Navigation Links
NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
Date:2/13/2008

DENVER, Feb. 13 /PRNewswire/ -- Rocky Mountain Biosystems, Inc.(R) (RMBI), a Denver area biomedical technology company, announced receipt of a grant award of approximately $600,000 over two years from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH) to develop its Self-Administered Vaccination Electromechanical (SAVE) technology for influenza vaccination. In the event of a pandemic, this needle-free system could be rapidly disseminated to provide protection against a deadly influenza outbreak, such as H5N1 influenza or bird flu. RMBI's technology has the potential to improve vaccine effectiveness to protect against a range of agents, including potential bioterror agents, by delivering therapeutics directly through the skin without needles, thus reducing required dosage and extending vaccine supplies. The RMBI technology and research may also improve population protection against annual seasonal influenza.

The SAVE device design is a lightweight, wristwatch-size vaccination system that delivers the vaccine in minutes, at pennies per application. "With RMBI's SAVE technology, we believe we can deliver vaccine protection to nearly all of the U.S. population within days of an outbreak. In addition, the effectiveness of RMBI's technology may reduce the amount of vaccine required, as well as provide greater immunity to the very young and elderly," noted Kevin Marchitto, RMBI's CEO.

RMBI's direct delivery through the skin is designed to 1) provide a means for individuals to immunize themselves, 2) rapidly deploy to hundreds of millions, within days of an emerging threat, 3) improve the lifetime and stability of vaccines, and their ability to be stored for long duration, and 4) improve vaccine efficiency and effectiveness to minimize chronic vaccine supply problems.

The SAVE vaccine delivery technology is being developed at Rocky Mountain Biosystems, Inc., a 6-year-old biomedical company located in the Denver metro area. RMBI blends technologies with experience to improve medical outcomes through tissue sealing and transdermal drug delivery technology to improve delivery and absorption of vaccines and therapeutics.

This release was issued through WebWire(R). For more information visit http://www.webwire.com.


'/>"/>
SOURCE Rocky Mountain Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... and CEO, Jim Joyce . In ... Saturday, Bill Gates warned world leaders that ... nuclear weapons. Mr. Gates expressed his concern, which is ... scientific terrorists have access to the necessary tools to ...
(Date:2/24/2017)... KONG, Feb. 24, 2017 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its unaudited financial results for the third ... ended December 31, 2016. Third Quarter of ... third quarter of fiscal 2017 increased by 18.6% to ...
(Date:2/24/2017)... 2017  VWR Corporation (NASDAQ: VWR), the leading global independent ... customers, today reported its financial results for the fourth quarter ... 4Q16 record quarterly net sales of ... organic basis. 4Q16 EMEA-APAC segment ... while the Americas net sales increased 2.5%, or down 0.9% ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
Breaking Biology Technology:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):